<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Factor VIII, recombinant human: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Factor VIII, recombinant human: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Factor VIII, recombinant human: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9723" href="/d/html/9723.html" rel="external">see "Factor VIII, recombinant human: Drug information"</a> and <a class="drug drug_patient" data-topicid="11469" href="/d/html/11469.html" rel="external">see "Factor VIII, recombinant human: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F135784"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Advate;</li>
<li>Afstyla;</li>
<li>Kogenate FS;</li>
<li>Kovaltry;</li>
<li>Novoeight;</li>
<li>Nuwiq;</li>
<li>Recombinate;</li>
<li>Xyntha;</li>
<li>Xyntha Solofuse</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865946"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Advate;</li>
<li>Kovaltry;</li>
<li>Nuwiq;</li>
<li>Xyntha;</li>
<li>Xyntha Solofuse;</li>
<li>Zonovate</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1051146"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihemophilic Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F53462373"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="41bca916-fbad-4b58-b634-e51fe53bc8d4">Hemophilia A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia A: </b>Individualize dosage based on clinical response and factor VIII activity evaluated at baseline and at regular intervals during treatment. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2% of normal. Patients with inhibitory antibodies to factor VIII may require higher doses, more frequent administration, and/or selection of alternative therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General dosing for control and prevention of bleeding episodes or perioperative management: </b>IV: <b>Note: </b>Dosage is expressed in units of factor VIII activity and must be individualized based on formulation, severity of factor VIII deficiency, extent and location of bleed, individualized incremental recovery using factor VIII activity assays, and clinical situation of patient.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Formula for units required to raise blood level: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Number of Factor VIII Units required = body weight (in kg) x 0.5 units/kg per units/dL x desired factor VIII level increase (units/dL or %)</p>
<p style="text-indent:-2em;margin-left:10em;">For example, for a desired 100% level in a 3 kg patient who has an actual level of 20%: Number of Factor VIII Units needed = 3 kg x 0.5 units/kg per units/dL x 80% = 120 units</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>):</i>
<b>Note:</b> Factor VIII level may either be expressed as % or as units/dL.</p>
<p style="text-indent:-2em;margin-left:8em;">Intermittent IV: The following recommendations reflect WFH guidelines for higher-dose practice patterns; this dosing is typically used in areas where no significant resource constraints exist; recommendations may vary from those found within prescribing information or practitioner preference. Frequency is based on type of bleed or surgery and varies by product; see specific product labeling for details. If Factor VIII levels are available, subsequent doses should be based on the half-life of factor VIII and on the recovery in an individual patient for a particular product.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Site of Hemorrhage/Clinical Situation</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Desired Factor VIII Peak Level</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Frequency<sup>A</sup></b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Duration</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>A</sup>Frequency is based on type of bleed or surgery and varies by product; see specific product labeling for details.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Joint</p></td>
<td align="center">
<p style="text-indent:0em;">40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours; <i>some products recommend more frequent (every 8 to 24 hours) for patients &lt;6 years</i></p></td>
<td align="center">
<p style="text-indent:0em;">1 to 2 days, may be longer if response is inadequate</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Superficial muscle/no neurovascular compromise</p></td>
<td align="center">
<p style="text-indent:0em;">40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours; <i>some products recommend more frequent (every 8 to 24 hours) for patients &lt;6 years</i></p></td>
<td align="center">
<p style="text-indent:0em;">2 to 3 days, sometimes longer if response is inadequate</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 80% to 100%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 8 to 24 hours; <i>some products recommend more frequent (every 6 to 12 hours) for patients &lt;6 years</i></p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 2 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 3 to 5 days, sometimes longer as secondary prophylaxis during physiotherapy</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">CNS/Head</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 80% to 100%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 8 to 24 hours; <i>some products recommend more frequent (every 6 to 12 hours) for patients &lt;6 years</i></p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 7 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 8 to 21 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Throat and neck</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 80% to 100%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 8 to 24 hours; <i>some products recommend more frequent (every 6 to 12 hours) for patients &lt;6 years</i></p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 7 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 8 to 14 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Gastrointestinal</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 80% to 100%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 8 to 24 hours; <i>some products recommend more frequent (every 6 to 12 hours) for patients &lt;6 years</i></p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 7 to 14 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> Not specified</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Renal</p></td>
<td align="center">
<p style="text-indent:0em;">50%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours; <i>some products recommend more frequent (every 8 to 24 hours) for patients &lt;6 years</i></p></td>
<td align="center">
<p style="text-indent:0em;">3 to 5 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Deep laceration</p></td>
<td align="center">
<p style="text-indent:0em;">50%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours; <i>some products recommend more frequent (every 8 to 24 hours) for patients &lt;6 years</i></p></td>
<td align="center">
<p style="text-indent:0em;">5 to 7 days</p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;">Surgery (major)</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Preop:</i> 80% to 100%</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 60% to 80%</p></td>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Every 8 to 24 hours; <i>some products recommend more frequent (every 6 to 24 hours) dosing for patients &lt;6 years</i></p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 1 to 3 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 4 to 6 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 30% to 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 7 to 14 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Surgery (minor)</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Preop:</i> 50% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 30% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 1 to 5 days depending on procedure type</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Routine prophylaxis: Note:</b> Maintain factor VIII trough levels &gt;3% to 5% or higher as clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Advate:</i> IV: 20 to 40 units/kg/dose every other day (3 to 4 times weekly). Alternatively, an every-third-day dosing regimen may be used to target factor VIII trough levels of ≥1%.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Afstyla</i>: <i>IV: </i>30 to 50 units/kg/dose 2 to 3 times weekly; more frequent or higher doses may be needed due to higher clearance in this age.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Helixate FS, Kogenate FS:</i> IV: 25 units/kg/dose given every other day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Kolvatry:</i> IV: 20 to 50 units/kg/dose 2 to 3 times weekly; alternatively, may administer every other day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Novoeight:</i> IV: 25 to 60 units/kg/dose 3 times weekly <b>or</b> 25 to 50 units/kg/dose every other day.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F135795"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="41bca916-fbad-4b58-b634-e51fe53bc8d4">Hemophilia A</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia A: </b>Individualize dosage based on clinical response and factor VIII activity evaluated at baseline and at regular intervals during treatment. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2% of normal. Patients with inhibitory antibodies to factor VIII may require higher doses, more frequent administration, and/or selection of alternative therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General dosing for control and prevention of bleeding episodes or perioperative management: Note: </b>Dosage is expressed in units of factor VIII activity and must be individualized based on formulation, severity of factor VIII deficiency, extent and location of bleed, individualized incremental recovery using factor VIII activity assays, and clinical situation of patient.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Formula for units required to raise blood level:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Number of Factor VIII Units required = body weight (in kg) x 0.5 units/kg per units/dL x desired factor VIII level increase (units/dL or %)</p>
<p style="text-indent:-2em;margin-left:10em;">For example, for a desired 100% level in a 25 kg patient who has an actual level of 20%: Number of Factor VIII Units needed = 25 kg x 0.5 units/kg per units/dL x 80% = 1,000 units</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>):</i>
<b>Note:</b> Factor VIII level may either be expressed as % or as units/dL.</p>
<p style="text-indent:-2em;margin-left:10em;">Intermittent IV: Infants, Children, and Adolescents: The following recommendations reflect WFH guidelines for higher-dose practice patterns; this dosing is typically used in areas where no significant resource constraints exist; recommendations may vary from those found within prescribing information or practitioner preference. Frequency is based on type of bleed or surgery and varies by product; see specific product labeling for details. Dosing frequency most commonly corresponds to the half-life of factor VIII but should be determined based on an assessment of factor VIII levels (if available) before the next dose.</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Site of Hemorrhage/Clinical Situation</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Desired Factor VIII Peak Level</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Frequency<sup>A</sup></b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Duration</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>A</sup>Frequency is based on type of bleed or surgery and varies by product; see specific product labeling for details.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Joint</p></td>
<td align="center">
<p style="text-indent:0em;">40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours; <i>some products recommend more frequent (every 8 to 24 hours) for patients &lt;6 years</i></p></td>
<td align="center">
<p style="text-indent:0em;">1 to 2 days, may be longer if response is inadequate</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Superficial muscle/no neurovascular compromise</p></td>
<td align="center">
<p style="text-indent:0em;">40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours; <i>some products recommend more frequent (every 8 to 24 hours) for patients &lt;6 years</i></p></td>
<td align="center">
<p style="text-indent:0em;">2 to 3 days, sometimes longer if response is inadequate</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 80% to 100%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 8 to 24 hours; <i>some products recommend more frequent (every 6 to 12 hours) for patients &lt;6 years</i></p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 2 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 3 to 5 days, sometimes longer as secondary prophylaxis during physiotherapy</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">CNS/Head</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 80% to 100%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 8 to 24 hours; <i>some products recommend more frequent (every 6 to 12 hours) for patients &lt;6 years</i></p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 7 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 8 to 21 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Throat and neck</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 80% to 100%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 8 to 24 hours; <i>some products recommend more frequent (every 6 to 12 hours) for patients &lt;6 years</i></p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 7 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 8 to 14 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Gastrointestinal</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 80% to 100%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 8 to 24 hours; <i>some products recommend more frequent (every 6 to 12 hours) for patients &lt;6 years</i></p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 7 to 14 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> Not specified</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Renal</p></td>
<td align="center">
<p style="text-indent:0em;">50%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours; <i>some products recommend more frequent (every 8 to 24 hours) for patients &lt;6 years</i></p></td>
<td align="center">
<p style="text-indent:0em;">3 to 5 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Deep laceration</p></td>
<td align="center">
<p style="text-indent:0em;">50%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours; <i>some products recommend more frequent (every 8 to 24 hours) for patients &lt;6 years</i></p></td>
<td align="center">
<p style="text-indent:0em;">5 to 7 days</p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;">Surgery (major)</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Preop:</i> 80% to 100%</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 60% to 80%</p></td>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Every 8 to 24 hours; <i>some products recommend more frequent (every 6 to 24 hours) dosing for patients &lt;6 years</i></p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 1 to 3 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 4 to 6 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 30% to 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 7 to 14 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Surgery (minor)</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Preop:</i> 50% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 30% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 1 to 5 days depending on procedure type</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:10em;">Continuous IV infusion: Infants, Children, and Adolescents: <b>Note: </b>In general, administration of factor VIII 4 units/kg/hour will increase circulating factor VIII levels by 1 unit/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26674820']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26674820'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Control and prevention of bleeding episodes: </i>Limited data available: <b>Note:</b> For patients who require prolonged periods of treatment (eg, intracranial hemorrhage or surgery) to avoid peaks and troughs associated with intermittent infusions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12010406','lexi-content-ref-22503305','lexi-content-ref-26674820','lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12010406','lexi-content-ref-22503305','lexi-content-ref-26674820','lexi-content-ref-32744769'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:14em;">Following initial bolus to achieve the desired factor VIII level: Initial dosing: 2 to 4 units/kg/hour; adjust dose based on frequent factor VIII assays and calculation of factor VIII clearance at steady-state using the following equations:</p>
<p style="text-indent:-2em;margin-left:14em;">Factor VIII clearance (mL/kg/hour) = (current infusion rate in units/kg/hour) / (plasma Factor level in units/<b>mL</b>)</p>
<p style="text-indent:-2em;margin-left:14em;">New infusion rate (units/kg/hour) = (factor VIII clearance in mL/kg/hour) x (desired plasma level in units/<b>mL</b>)</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Perioperative</i>
<i> management: </i>Limited data available: Initial: 25 to 50 units/kg prior to surgery, followed by continuous infusion at a rate of 3 to 5 units/kg/hour; regimen based on 2 studies evaluating use in pediatric surgery patients (age range: 0.9 to 17 years); rate was adjusted and additional boluses given as needed to maintain desired factor VIII level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22530687','lexi-content-ref-12199670']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22530687','lexi-content-ref-12199670'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Routine prophylaxis: Note:</b> Maintain factor VIII trough levels &gt;3% to 5% or higher as clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Product-specific dosing:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Advate:</i> Infants, Children, and Adolescents: IV: 20 to 40 units/kg/dose every other day (3 to 4 times weekly). Alternatively, an every-third-day dosing regimen may be used to target factor VIII trough levels of ≥1%.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Afstyla:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Infants and Children &lt;12 years: IV: 30 to 50 units/kg/dose 2 to 3 times weekly; more frequent or higher doses may be required due to higher drug clearance.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥12 years and Adolescents: IV: 20 to 50 units/kg/dose 2 to 3 times weekly.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Helixate FS, Kogenate FS:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Infants, Children, and Adolescents ≤16 years: IV: 25 units/kg/dose given every other day.</p>
<p style="text-indent:-2em;margin-left:10em;">Adolescents &gt;16 years: IV: 25 units/kg/dose 3 times a week.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Kovaltry:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Infants and Children: IV: 20 to 50 units/kg/dose every other day, twice weekly or 3 times weekly, dependent on patient response.</p>
<p style="text-indent:-2em;margin-left:10em;">Adolescents: IV: 20 to 40 units/kg/dose 2 to 3 times weekly.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Novoeight</i>:</p>
<p style="text-indent:-2em;margin-left:10em;">Infants and Children <i>&lt;</i>12 years: IV: 25 to 60 units/kg/dose 3 times weekly <b>or</b> 25 to 50 units/kg/dose every other day.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥12 years and Adolescents: IV: 20 to 50 units/kg/dose 3 times weekly <b>or</b> 20 to 40 units/kg/dose every other day.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Nuwiq:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Children 2 to 11 years: IV: 30 to 50 units/kg/dose every other day or 3 times weekly.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥12 years and Adolescents: IV: 30 to 40 units/kg/dose every other day.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Xyntha, Xyntha Solofuse:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Children &lt;12 years: IV: 25 units/kg/dose every other day; more frequent or higher doses may be required due to higher drug clearance.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥12 years and Adolescents: IV: 30 units/kg/dose 3 times weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Guideline dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>)</i>: <b>Note: </b>Dose should be individualized; dose intensity should take into account disease severity, patient's activity and lifestyle, and pharmacokinetic properties of product, and should be adjusted if breakthrough bleeding occurs. See guidelines for in-depth discussion of risks and benefits of each approach.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:10em;">High dose: 25 to 40 units/kg/dose every 2 days.</p>
<p style="text-indent:-2em;margin-left:10em;">Intermediate dose: 15 to 25 units/kg/dose 3 times weekly.</p>
<p style="text-indent:-2em;margin-left:10em;">Low dose: 10 to 15 units/kg/dose 2 to 3 times weekly. <b>Note: </b>Low dose prophylaxis may be used in young patients as initial therapy to allow patients and families to gradually adjust to prophylaxis and improves adherence; close monitoring is required since patients are at a higher risk for bleeding until escalation occurs.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F54290958"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F54290959"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F135786"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9723" href="/d/html/9723.html" rel="external">see "Factor VIII, recombinant human: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="be400ab4-381a-4d5e-b65d-e32a52f7ab49">Hemophilia A, without inhibitors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia A, without inhibitors:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Treatment and control of bleeding episodes or perioperative management:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Intermittent IV bolus dosing: </i>IV: </b>Utilize steps 1 to 3 to determine intermittent bolus dosing strategy. Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment. In general, administration of factor VIII 1 unit/kg will increase circulating factor VIII levels by ~2 units/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 1:</b> Determine desired factor VIII peak level and anticipated duration of therapy based on the World Federation of Hemophilia (WFH) treatment recommendations; see table. Selection of the lower-dose practice pattern requires closer observation with the potential for requiring escalation to higher doses based on clinical response.</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> For patients without inhibitors and receiving emicizumab who experience breakthrough bleeding, antihemophilic factor should be dosed to target the desired peak factor VIII levels outlined in the table as emicizumab is not indicated for treatment of bleeding episodes.</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption>
<b>Antihemophilic Factor (Recombinant) WFH Treatment Recommendations<sup>d</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="bottom">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">
<b>Type of hemorrhage or surgery</b></p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;text-align:center;">
<b>Lower-dose practice pattern</b></p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;text-align:center;">
<b>Higher-dose practice pattern</b></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Desired peak factor VIII level (units/dL)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Treatment duration (days)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Desired peak factor VIII level (units/dL)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Treatment duration (days)</b></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="55">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>May be longer if response is inadequate.</p>
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Sometimes longer as secondary prophylaxis during physical therapy.</p>
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>A single dose may be sufficient for some joint bleeds; determine need for additional doses based on clinical response.</p>
<p style="text-indent:0em;text-align:left;">
<sup>d </sup>WFH [Srivastava 2020].</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Joint</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2<sup>a,c</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2<sup>a,c</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Superficial muscle/no neurovascular compromise (except iliopsoas)</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to 3<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to 3<sup>a</sup></p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Iliopsoas or deep muscle with neurovascular injury or substantial blood loss: </b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5<sup>b</sup></p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Intracranial</b>:</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 7</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 21</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Throat and Neck:</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 7</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 14</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Gastrointestinal:</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Renal</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Deep laceration</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 to 7</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Surgery (major):</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Preop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">80 to 100</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Postop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 6</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 6</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td></tr>
<tr>
<td align="center" colspan="55">
<p style="text-indent:0em;text-align:left;">
<b>Surgery (minor):</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Preop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Postop</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 5</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 2:</b> Calculate dose using desired peak factor VIII level from step 1 and the following equation:</p>
<p style="text-indent:-2em;margin-left:10em;">Factor VIII units required = [(desired peak factor VIII level − patient's baseline factor VIII level) × body weight (kg)]/2</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Factor VIII level units are units/dL.</p>
<p style="text-indent:-2em;margin-left:10em;">Example for 50 kg patient with desired peak factor VIII level of 35 units/dL and baseline factor VIII level of 5 units/dL:</p>
<p style="text-indent:-2em;margin-left:10em;">Factor VIII units required = [(35 units/dL − 5 units/dL) × 50 kg]/2 = 750 units of factor VIII</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Step 3:</b> Determine need for repeat dosing based on manufacturer's recommended frequency of repeat dosing. <b>Note:</b> Frequency of administration must also take into consideration subsequent factor VIII activity measurements and the clinical response.</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<caption>
<b>Antihemophilic Factor (Recombinant) Administration Frequency According to Clinical Scenario</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="bottom">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Product</p></th>
<th align="center" colspan="3">
<p style="text-indent:0em;">Bleeding event</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Surgery</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Minor severity</p></th>
<th align="center">
<p style="text-indent:0em;">Moderate severity</p></th>
<th align="center">
<p style="text-indent:0em;">Major severity</p></th>
<th align="center">
<p style="text-indent:0em;">Minor bleeding risk</p></th>
<th align="center">
<p style="text-indent:0em;">Major bleeding risk</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">Advate</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Afstyla</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Kogenate FS</p></td>
<td align="center">
<p style="text-indent:0em;">Repeat × 1 if evidence of further bleeding</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 12 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 6 to 12 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Kovaltry</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Novoeight</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Nuwiq</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Recombinate</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">A single dose typically adequate</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Xyntha/Xyntha Solofuse</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Zonovate (Canadian product)</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;margin-top:2em;">
<i>
<b>Continuous infusion dosing</b></i>
<i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12010406','lexi-content-ref-22530687','lexi-content-ref-28873263','lexi-content-ref-1482660','lexi-content-ref-22503305','lexi-content-ref-Rickard.1','lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12010406','lexi-content-ref-22530687','lexi-content-ref-28873263','lexi-content-ref-1482660','lexi-content-ref-22503305','lexi-content-ref-Rickard.1','lexi-content-ref-32744769'])">Ref</a></span>):</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Continuous infusion administration is preferred over intermittent bolus administration for patients requiring prolonged treatment courses (eg, postoperative management after surgery with major bleeding risk). To ensure safe and effective use, only products with extended stability information should be used. Extended stability information may not be available for all products; contact product manufacturer to obtain current recommendations. Use of a smart infusion pump with small volume infusion capability is also necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> Administer an initial bolus to achieve the desired factor VIII level (see steps 1 and 2 under intermittent bolus dosing), then initiate continuous infusion at 2 to 4 units/kg/hour. Adjust dose based on frequent factor assays (at least daily) and calculation of factor VIII clearance at steady-state using the below equations.</p>
<p style="text-indent:-2em;margin-left:10em;">Factor VIII clearance (mL/kg/hour) = (current infusion rate in units/kg/hour) divided by (measured factor VIII level in units/mL)</p>
<p style="text-indent:-2em;margin-left:10em;">New infusion rate (units/kg/hour) = (factor VIII clearance in mL/kg/hour) x (desired factor VIII level in units/mL)</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> With infusion dose increases, re-bolus should be considered to achieve target factor VIII level more quickly. See steps 1 and 2 under intermittent bolus dosing to determine re-bolus dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Routine prophylaxis to prevent or reduce the frequency of bleeding episodes:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Preferably, dosing should be tailored to ensure trough factor VIII levels of at least 1% and ideally ≥3 to 5% are achieved, but prophylaxis targets should be tailored to individual level of activity, lifestyle, and pharmacokinetics. Dose escalation should be considered for patients adherent to prescribed prophylaxis but still experiencing breakthrough bleeding events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32744769'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Advate:</i>
<b>IV:</b> 20 to 40 units/kg every other day (3 to 4 times weekly). Alternatively, an every-third-day dosing regimen may be used to target factor VIII trough levels of ≥1%.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Afstyla:</i>
<b>IV:</b> 20 to 50 units/kg 2 to 3 times weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Kogenate FS:</i>
<b>IV:</b> 25 units/kg 3 times weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Kovaltry:</i>
<b>IV:</b> 20 to 40 units/kg 2 or 3 times weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Novoeight:</i>
<b>IV:</b> 20 to 50 units/kg 3 times weekly <b>or</b> 20 to 40 units/kg every other day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Nuwiq:</i>
<b>IV:</b> 30 to 40 units/kg every other day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Xyntha/Xyntha Solofuse</i>: <b>IV:</b> 30 units/kg 3 times weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Zonovate [Canadian product]:</i>
<b>IV:</b> 20 to 50 units/kg 3 times weekly <b>or</b> 20 to 40 units/kg every other day.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991107"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988408"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F135763"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Actual frequency may vary by product and population. Reported adverse reactions are for adults and pediatrics.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (≤16%), skin rash (≤16%), urticaria (≤16%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Increased factor VIII inhibitors (previously untreated patients/minimally treated patients: 50% to 55%; previously treated patients: &lt;1%; may include neutralizing antibodies)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (9% to 24%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (5% to 23%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (10% to 13%), nasopharyngitis (12%), upper respiratory tract infection (7% to 22%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (9%; previously untreated patients/minimally treated patients: 30%; previously treated patents: 4%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (1%), abdominal pain (4%), diarrhea (5% to 8%), dyspepsia (2%), vomiting (3% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Varicella zoster infection (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion-site reaction (4% to 7%), injection-site reaction (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (6%), chills (≤7%), dizziness (≤2%), insomnia (1% to 2%), malaise (1%), procedural pain (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (4%), limb injury (6%), limb pain (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic:<b></b>Otic infection (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (1%), lower respiratory tract infection (8%), nasal congestion (6%), pharyngitis (5%), pharyngolaryngeal pain (5%), rhinitis (8%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort, cold extremity, flushing, hypotension, palpitations, sinus tachycardia, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic dermatitis, erythema of skin, hyperhidrosis, maculopapular rash, pallor</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hematoma, lymphadenopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Inflammation at injection site, pain at injection site</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue, feeling hot, neurological deterioration, paresthesia, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal neoplasm (benign)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Endocrine &amp; metabolic: Hot flash</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, facial edema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Loss of consciousness, restlessness</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cyanosis, laryngeal edema</p></div>
<div class="block coi drugH1Div" id="F135776"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity (eg, anaphylaxis) to antihemophilic factor, mouse or hamster protein (Advate, Afstyla, Kogenate FS, Kovaltry, Novoeight, Recombinate, Xyntha, Zonovate [Canadian product]), bovine protein (Recombinate only), or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F135760"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: The development of factor VIII antibodies has been reported with antihemophilic factors; monitor for signs of formation of antibodies to factor VIII; may occur at any time but more common in young children with severe hemophilia and previously untreated patients. Suspect factor VIII antibodies if the plasma factor VIII level does not increase as expected or if bleeding is not controlled after administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Allergic hypersensitivity reactions (including anaphylaxis) may occur; discontinue if hypersensitivity symptoms occur and administer appropriate treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Albumin: Recombinate is stabilized using human albumin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bovine: Recombinate may contain bovine protein.</p>
<p style="text-indent:-2em;margin-left:4em;">• Mouse/hamster protein: Some products may contain trace amounts of mouse or hamster protein.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sucrose: Some products are stabilized with or may contain sucrose.</p>
<p style="text-indent:-2em;margin-left:4em;">• von Willebrand factor: Some products contain naturally-occurring von Willebrand factor for stabilization; however, efficacy has not been established for the treatment of von Willebrand disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dose requirements: The dosage requirement will vary in patients with factor VIII inhibitors; optimal treatment should be determined by clinical response.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878331"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;">Allergic-type hypersensitivity reactions including anaphylaxis may occur; discontinue therapy immediately if urticaria, hives, hypotension, tightness of the chest, wheezing, or anaphylaxis develop; emergency treatment and resuscitative measures (eg, epinephrine, oxygen) may be needed. Clinical response to antihemophilic factor administration may vary; dosage must be individualized based on coagulation studies (performed prior to treatment and at regular intervals during treatment) and clinical response. If bleeding is not controlled with the recommended dose, determine plasma level of factor VIII and follow with a sufficient dose to achieve satisfactory clinical response. If plasma levels of factor VIII fail to increase as expected or bleeding continues, suspect the presence of an inhibitor; test as appropriate. Formation of factor VIII inhibitors (neutralizing antibodies to AHF recombinant) may occur at any time, but is more common in young children with severe hemophilia during the first years of therapy, or in patients at any age who received little prior therapy with factor VIII; monitor patients appropriately.</p></div>
<div class="block dosfc drugH1Div" id="F25573579"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Strengths expressed with approximate values.  Consult individual vial labels for exact potency within each vial.</p></div>
<div class="block foc drugH1Div" id="F135770"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kogenate FS: 250 units, 500 units, 1000 units</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Afstyla: 250 units, 500 units, 1000 units, 1500 units, 2000 units, 2500 units, 3000 units [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kogenate FS: 2000 units, 3000 units</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nuwiq: 250 units, 500 units, 1000 units, 2000 units, 2500 units, 3000 units, 4000 units</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xyntha: 250 units, 500 units, 1000 units, 2000 units [albumin free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xyntha Solofuse: 250 units, 500 units, 1000 units, 2000 units, 3000 units [albumin free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kovaltry: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea); 3000 units (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Advate: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 1500 units (1 ea); 2000 units (1 ea); 3000 units (1 ea); 4000 units (1 ea) [albumin free; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Novoeight: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 1500 units (1 ea); 2000 units (1 ea); 3000 units (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nuwiq: 1500 units (1 ea) [latex free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nuwiq: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea); 2500 units (1 ea); 3000 units (1 ea); 4000 units (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Recombinate: 220-400 units (1 ea); 401-800 units (1 ea); 801-1240 units (1 ea); 1241-1800 units (1 ea); 1801-2400 units (1 ea) [contains albumin human, polyethylene glycol (macrogol), polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F135756"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F21121604"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Afstyla Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 unit (Price provided is per AHF Unit): $2.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $2.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $2.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1500 unit (Price provided is per AHF Unit): $2.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 unit (Price provided is per AHF Unit): $2.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2500 unit (Price provided is per AHF Unit): $2.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000 unit (Price provided is per AHF Unit): $2.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Kogenate FS Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 unit (Price provided is per AHF Unit): $2.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $2.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $2.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 unit (Price provided is per AHF Unit): $2.42</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000 unit (Price provided is per AHF Unit): $2.42</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Nuwiq Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2500 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4000 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Xyntha Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 unit (Price provided is per AHF Unit): $2.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $2.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $2.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 unit (Price provided is per AHF Unit): $2.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (Xyntha Solofuse Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 unit (Price provided is per AHF Unit): $2.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $2.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $2.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 unit (Price provided is per AHF Unit): $2.18</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000 unit (Price provided is per AHF Unit): $2.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Advate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1500 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4000 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Kovaltry Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 unit (per each): $2.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $2.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (per each): $2.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (per each): $2.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 unit (per each): $2.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000 unit (per each): $2.64</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Novoeight Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 unit (Price provided is per AHF Unit): $2.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $2.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $2.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1500 unit (Price provided is per AHF Unit): $2.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 unit (Price provided is per AHF Unit): $2.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000 unit (Price provided is per AHF Unit): $2.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Nuwiq Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1500 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2500 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4000 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Recombinate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">220-400 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">401-800 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">801-1240 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1241-1800 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1801-2400 unit (Price provided is per AHF Unit): $2.28</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865947"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xyntha: 250 units, 500 units [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xyntha Solofuse: 500 units, 1000 units, 2000 units, 3000 units [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Advate: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 1500 units (1 ea); 2000 units (1 ea); 3000 units (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Kovaltry: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea); 3000 units (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nuwiq: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea); 3000 units (1 ea); 4000 units (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zonovate: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 1500 units (1 ea); 2000 units (1 ea); 3000 units (1 ea) [contains polysorbate 80]</p></div>
<div class="block adip drugH1Div" id="F53565351"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">One unit of rAHF is equal to the factor VIII activity present in 1 mL of fresh pooled human plasma. If bleeding is not controlled with adequate dose, test for the presence of factor VIII inhibitor; larger doses of rAHF may be therapeutic with inhibitor titers &lt;10 Bethesda units/mL; it may not be possible or practical to control bleeding if inhibitor titers &gt;10 Bethesda units/mL (due to the very large rAHF doses required); other treatments (eg, antihemophilic factor [porcine], factor IX complex concentrates, recombinant factor VIIa, or anti-inhibitor coagulant complex) may be needed in patients with inhibitor titers &gt;10 Bethesda units/mL.</p></div>
<div class="block admp drugH1Div" id="F52612246"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV administration only; use administration sets/tubing provided by manufacturer (if provided). Adjust administration rate based on patient response.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV: Rate of administration should be determined by patient tolerability (maximum rates vary by product).</p>
<p style="text-indent:-2em;margin-left:6em;">Advate: Infuse over ≤5 minutes; maximum infusion rate: 10 mL/minute.</p>
<p style="text-indent:-2em;margin-left:6em;">Afstyla: Infuse up to a maximum infusion rate of 10 mL/minute.</p>
<p style="text-indent:-2em;margin-left:6em;">Helixate FS, Kogenate FS, Kovaltry: Infuse over 1 to 15 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">Novoeight: Infuse slowly over 2 to 5 minutes.</p>
<p style="text-indent:-2em;margin-left:6em;">Nuwiq: Infuse up to a maximum infusion rate of 4 mL/minute.</p>
<p style="text-indent:-2em;margin-left:6em;">Recombinate: Infuse at a maximum rate of 5 mL/minute when reconstituted with 5 mL of SWFI.</p>
<p style="text-indent:-2em;margin-left:6em;">Xyntha, Xyntha Solofuse: Infuse over several minutes. Do not admix or administer in same tubing as other medications.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Further dilution after initial reconstitution is unnecessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22530687','lexi-content-ref-26674820']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22530687','lexi-content-ref-26674820'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F135773"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Rate of administration should be determined by patient tolerability (maximum rates vary by product).</p>
<p style="text-indent:-2em;margin-left:4em;">Advate: Infuse over ≤5 minutes (maximum: 10 mL/minute)</p>
<p style="text-indent:-2em;margin-left:4em;">Afstyla: Infuse up to a maximum rate of 10 mL/minute</p>
<p style="text-indent:-2em;margin-left:4em;">Kogenate FS, Kovaltry: Infuse over 1 to 15 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Novoeight: Infuse slowly over 2 to 5 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Nuwiq: Infuse up to a maximum rate of 4 mL/minute</p>
<p style="text-indent:-2em;margin-left:4em;">Recombinate: Infuse up to a maximum rate of 5 mL/minute</p>
<p style="text-indent:-2em;margin-left:4em;">Xyntha, Xyntha Solofuse: Infuse over several minutes. Do not admix or administer in same tubing as other medications.</p>
<p style="text-indent:-2em;margin-left:4em;">Zonovate [Canadian product]: Infuse at a rate of 1 to 2 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">Continuous infusion (off-label rate): Has also been administered as a continuous infusion to avoid peaks and troughs associated with intermittent infusions in patients who require prolonged treatment periods. Use a smart infusion pump with small volume infusion capability. Refer to protocols for product selection and preparation details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12010406','lexi-content-ref-22530687','lexi-content-ref-28873263','lexi-content-ref-22503305','lexi-content-ref-Rickard.1','lexi-content-ref-27704637','lexi-content-ref-32744769']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12010406','lexi-content-ref-22530687','lexi-content-ref-28873263','lexi-content-ref-22503305','lexi-content-ref-Rickard.1','lexi-content-ref-27704637','lexi-content-ref-32744769'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F135782"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Prior to reconstitution, store refrigerated at 2°C to 8°C (36°F to 46°F); do not freeze. Do not refrigerate after reconstitution (unless otherwise noted).</p>
<p style="text-indent:-2em;margin-left:2em;">Additional product-specific storage information:</p>
<p style="text-indent:-2em;margin-left:4em;">Advate: May also be stored at room temperature (not to exceed 30°C [86°F]) up to 6 months; do not return to refrigerator. Use within 3 hours of reconstitution.</p>
<p style="text-indent:-2em;margin-left:4em;">Afstyla: May also be stored at room temperature (not to exceed 25°C [77°F]) up to 3 months; do not return to refrigerator. Store in original package to protect from light. Use within 4 hours of reconstitution.</p>
<p style="text-indent:-2em;margin-left:4em;">Kogenate FS, Kovaltry: May also be stored at room temperature (not to exceed 25°C [77°F]) up to 12 months; do not return to refrigerator. Protect from extreme exposure to light during storage. Use within 3 hours of reconstitution.</p>
<p style="text-indent:-2em;margin-left:4em;">Novoeight: Store in original package to protect from light. May also be stored at room temperature:</p>
<p style="text-indent:-2em;margin-left:6em;">≤30°C (86°F) for up to 12 months; do not return to refrigerator; must be used within 4 hours of reconstitution if stored at this temperature</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;30°C to ≤40°C (&gt;86°F to 104°F) for up to 3 months; do not return to refrigerator; must be used within 2 hours of reconstitution if stored at this temperature</p>
<p style="text-indent:-2em;margin-left:4em;">Nuwiq: May also be stored at room temperature (not to exceed 25°C [77°F]) up to 3 months; do not return to refrigerator. Store in original package to protect from light. Use within 3 hours of reconstitution.</p>
<p style="text-indent:-2em;margin-left:4em;">Recombinate: May also be stored at room temperature, not to exceed 30°C (86°F). Use within 3 hours of reconstitution.</p>
<p style="text-indent:-2em;margin-left:4em;">Xyntha: May also be stored at room temperature (not to exceed 25°C [77°F]) up to 3 months; after room temperature storage, product may be returned to the refrigerator until the expiration date; however, do not store at room temperature and return to refrigerator temperature more than once. Avoid prolonged exposure to light during storage. Use within 3 hours of reconstitution.</p>
<p style="text-indent:-2em;margin-left:4em;">Xyntha Solofuse: May also be stored at room temperature not to exceed 25°C [77°F]) up to 3 months; do not return to refrigerator; after 3 months at room temperature, must use immediately or discard. Use within 3 hours of reconstitution.</p>
<p style="text-indent:-2em;margin-left:4em;">Zonovate (Canadian product): Store intact vial in original package to protect from light. Following reconstitution, use immediately or may store at 2°C to 8°C (36°F to 46°F) but must be used within 24 hours. Store reconstituted product in the vial, with vial adapter and syringe still attached and out of direct light; discard any unused reconstituted product. May also be stored at room temperature:</p>
<p style="text-indent:-2em;margin-left:6em;">≤30°C (86°F) for up to 12 months; do not return to refrigerator; must be used within 4 hours of reconstitution if stored at this temperature.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;30°C to ≤40°C (&gt;86°F to 104°F) for up to 3 months; do not return to refrigerator; must be used within 2 hours of reconstitution if stored at this temperature.</p></div>
<div class="block usep drugH1Div" id="F53565471"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">
<b>Note: Antihemophilic Factor (Recombinant) is not indicated for the treatment of von Willebrand disease.</b></p>
<p style="text-indent:-2em;margin-left:2em;">Advate, Afstyla, Novoeight: On-demand treatment and control of bleeding episodes in patients with hemophilia A; perioperative management of patients with hemophilia A; routine prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A (All indications: FDA approved in all ages).</p>
<p style="text-indent:-2em;margin-left:2em;">Helixate FS, Kogenate FS: On-demand treatment and control of bleeding episodes in patients with hemophilia A (FDA approved in all ages); perioperative management of patients with hemophilia A (FDA approved in all ages); routine prophylaxis to reduce the frequency of bleeding episodes and reduce the risk of joint damage in children with hemophilia A with no preexisting joint damage (FDA approved in ages 0 to 16 years); routine prophylaxis to reduce the frequency of bleeding episodes (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Kovaltry: Prevention and control of bleeding episodes in patients with hemophilia A; perioperative management of patients with hemophilia A; routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A (All indications: FDA approved in all ages).</p>
<p style="text-indent:-2em;margin-left:2em;">Nuwiq: On-demand treatment and control of bleeding episodes in patients with hemophilia A; perioperative management of patients with hemophilia A; routine prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A (All indications: FDA approved in ages &gt;2 and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Recombinate: Prevention and control of bleeding episodes in patients with hemophilia A; perioperative management of patients with hemophilia A (All indications: FDA approved in all ages).</p>
<p style="text-indent:-2em;margin-left:2em;">Xyntha, Xyntha Solofuse: On-demand treatment and control of bleeding episodes in patients with hemophilia A; perioperative management of patients with hemophilia A; routine prophylaxis to reduce the frequency of bleeding episodes in patients with hemophilia A (All indications: FDA approved in pediatric patients [age not specified] and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Has also been used in patients with acquired factor VIII inhibitors &lt;10 Bethesda units/mL.</p></div>
<div class="block mst drugH1Div" id="F6814324"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Factor VIII may be confused with Factor XIII</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Confusion may occur due to the omitting of  “Factor VIII” from some product labeling. Review product contents carefully prior to dispensing any antihemophilic factor.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298758"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6218001"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block dic drugH1Div" id="F3000257"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;text-align:justify;display:inline">Some products may contain sodium.</p></div>
<div class="block pri drugH1Div" id="F135778"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Pregnant carriers of hemophilia A may have an increased bleeding risk following invasive procedures, spontaneous miscarriage, termination of pregnancy, and delivery; close surveillance is recommended. Factor VIII levels should be monitored at the first antenatal visit, once or twice during the third trimester, prior to surgical or invasive procedures, and at delivery. Although factor VIII concentrations increase in pregnant patients, factor VIII replacement is recommended if concentrations are &lt;50 units/dL and any of the following occur: need for invasive procedures (including delivery), spontaneous miscarriage, insertion and removal of epidural catheters, or active bleeding. Hemostatic factor VIII concentrations should be maintained for at least 3 to 5 days following invasive procedures or postpartum. If a replacement product is indicated, a recombinant product is preferred (NHF 2017; RCOG [Pavord 2017]; WFH [Srivastava 2020]).</p></div>
<div class="block mopp drugH1Div" id="F53565446"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor factor VIII levels prior to and during treatment, heart rate and blood pressure (before and during IV administration). Monitor for signs and symptoms of bleeding, hemoglobin and hematocrit, and for hypersensitivity reactions; monitor for the development of inhibitor antibodies by clinical observations (eg, inadequate control of bleeding with adequate doses) and laboratory tests (eg, inhibitor level, Bethesda assay).</p></div>
<div class="block rerp drugH1Div" id="F53565350"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Classification of hemophilia; normal is defined as 1 unit/mL of factor VIII (WFH [Srivastava 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">Severe: Factor level &lt;1% of normal.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate: Factor level 1% to 5% of normal.</p>
<p style="text-indent:-2em;margin-left:4em;">Mild: Factor level 5% to &lt;40% of normal.</p></div>
<div class="block pha drugH1Div" id="F135759"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Factor VIII replacement, necessary for clot formation and maintenance of hemostasis. It activates factor X in conjunction with activated factor IX; activated factor X converts prothrombin to thrombin, which converts fibrinogen to fibrin, and with factor XIII forms a stable clot.</p></div>
<div class="block phk drugH1Div" id="F135775"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>ss</sub>: ~0.4 to 0.85 dL/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Advate: Children &lt;12 years: 8.7 to 11.2 hours; Adolescents and Adults: 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Afstyla: Children &lt;12 years: 10.2 to 10.4 hours; Children ≥12 years and Adolescents: 14.3 hours; Adults: 14.2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Kogenate FS: Children: 10.7 hours; Adults: 13.7 to 14.6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Kovaltry: Children &lt;12 years: ~12 hours; Children ≥12 years, Adolescents, and Adults: ~14 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Novoeight: Children &lt;12 years: 7.7 to 10 hours; Adolescents and Adults: 11 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Nuwiq: Children ≤12 years: 11.9 to 13.1 hours; Adolescents and Adults: 17.1 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Recombinate: Adults: 14.6 ± 4.9 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Xyntha, Xyntha Solofuse: Children 3.7 to 5.8 years: 8.3 ± 2.7 hours; Adolescents 14 to 15 years: 6.9 ± 2.4 hours; Adults: 11 to 17 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Zonovate [Canadian product]: Children ≤12 years: ~7.5 to 10 hours; Adolescents and Adults: ~11 to 12 hours.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F135779"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Advate | Recombinate</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate fs | Kovaltry</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Advate | Iblias | Kogenate | Kovaltry | Recombinate</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate | Recombinate</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Advate | Helixate nexgen | Kogenate | Kovaltry | Recombinate</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate | Kovaltry</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kovaltry</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Helixate M2V | Helixate nexgen | Kogenate SF | Kovaltry | Recombinate</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Kogenate</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate fs | Kovaltry | Recombinate</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Advate | Helixate nexgen | Kovaltry | Recombinate</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Advate | Iblias | Kogenate | Kovaltry | Recombinate</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Kogenate fs</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Advate | Recombinate</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Kogenate fs</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Advate | Helixate nexgen | Iblias | Kogenate | Kovaltry | Recombinate</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Advate | Helixate nexgen | Kogenate | Kovaltry | Recombinate</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Advate | Helixate nexgen | Kogenate | Kovaltry</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Advate | Helixate nexgen | Kogenate | Recombinate</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Advate | Helixate nexgen | Kogenate | Kovaltry</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate fs</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Helixate nexgen | Kogenate | Kovaltry</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Kogenate</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Advate | Helixate nexgen</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Recombinate</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Helixate nexgen</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate | Kovaltry</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Kogenate</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate | Kogenate fs | Recombinate</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate fs | Recombinate</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Kogenate</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Kogenate | Recombinate</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate bayer | Kovaltry</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Kogenate | Kovaltry</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate | Recombinate</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Kogenate</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate fs | Kovaltry | Recombinate</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate fs</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Advate | Helixate nexgen | Iblias | Kogenate | Kovaltry | Recombinate</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Advate | Helixate nexgen | Kovaltry</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate SF | Recombinate</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Kogenate bayer</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate fs | Kovaltry</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Advate | Helixate nexgen | Kogenate | Recombinate</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Kogenate fs</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Advate | Afstyla | Kogenate FS | Kovaltry | NovoEight | Xyntha | Xyntha Solofuse</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate bayer | Kovaltry | Recombinate</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate fs</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate | Recombinate</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Advate | Helixate nexgen | Kogenate bayer | Kovaltry | Recombinate</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate fs</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kovaltry</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate fs | Recombinate</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate fs</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kovaltry | Recombinate</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate | Kogenate fs | Kovaltry</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Advate | Kogenate fs | Recombinate</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Kogenate fs</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Kogenate | Kovaltry</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-10896230">
<a name="10896230"></a>Abshire TC, Brackmann HH, Scharrer I, et al, “Sucrose Formulated Recombinant Human Antihemophilic Factor VIII is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy. International Kogenate-FS Study Group,” <i>Thromb Haemost</i>, 2000, 83(6):811-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/10896230/pubmed" id="10896230" target="_blank">10896230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Advate.1">
<a name="Advate.1"></a>Advate (antihemophilic factor [recombinant]) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Afstyla.1">
<a name="Afstyla.1"></a>Afstyla (antihemophilic factor [recombinant]) [prescribing information]. Kankakee, IL: CSL Behring LLC; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Afstyla.1">
<a name="Afstyla.1"></a>Afstyla (antihemophilic factor [recombinant]) [prescribing information]. Kankakee, IL: CSL Behring LLC; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Afstyla.2">
<a name="Afstyla.2"></a>Afstyla (antihemophilic factor [recombinant]) [prescribing information]. Kankakee, IL: CSL Behring LLC; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22530687">
<a name="22530687"></a>Batorova A, Holme P, Gringeri A, et al; European Haemophilia Treatment Standardisation Board. Continuous infusion in haemophilia: current practice in Europe. <i>Haemophilia</i>. 2012;18(5):753-759. doi:10.1111/j.1365-2516.2012.02810.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/22530687/pubmed" id="22530687" target="_blank">22530687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12010406">
<a name="12010406"></a>Batorova A, Martinowitz U. Continuous infusion of coagulation factors. <i>Haemophilia</i>. 2002;8(3):170-177. doi:10.1046/j.1365-2516.2002.00635.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/12010406/pubmed" id="12010406" target="_blank">12010406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10997985">
<a name="10997985"></a>Batorova A, Martinowitz U. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery. <i>Br J Haematol</i>. 2000;110(3):715-720.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/10997985/pubmed" id="10997985" target="_blank">10997985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8167332">
<a name="8167332"></a>Bray GL, Gomperts ED, Courter S, et al, “A Multicenter Study of Recombinant Factor VIII (Recombinate): Safety, Efficacy, and Inhibitor Risk in Previously Untreated Patients With Hemophilia A. The Recombinate Study Group,” <i>Blood</i>, 1994, 83(9):2428-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/8167332/pubmed" id="8167332" target="_blank">8167332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20731726">
<a name="20731726"></a>Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S; International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. <i>Haemophilia.</i> 2011;17(1):2-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/20731726/pubmed" id="20731726" target="_blank">20731726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12199670">
<a name="12199670"></a>Dingli D, Gastineau DA, Gilchrist GS, Nichols WL, Wilke JL. Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates. <i>Haemophilia</i>. 2002;8(5):629-634.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/12199670/pubmed" id="12199670" target="_blank">12199670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28873263">
<a name="28873263"></a>Holme PA, Tjønnfjord GE, Batorova A. Continuous infusion of coagulation factor concentrates during intensive treatment. <i>Haemophilia</i>. 2018;24(1):24-32. doi:10.1111/hae.13331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/28873263/pubmed" id="28873263" target="_blank">28873263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9108849">
<a name="9108849"></a>Kelly KM, Butler RB, Farace L, et al, “Superior In Vivo Response of Recombinant Factor VIII Concentrate in Children With Hemophilia A,” <i>J Pediatr</i>, 1997, 130(4):537-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/9108849/pubmed" id="9108849" target="_blank">9108849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KogenateFS.1">
<a name="KogenateFS.1"></a>Kogenate FS (antihemophilic factor [recombinant]) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; May 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KogenateFS.1">
<a name="KogenateFS.1"></a>Kogenate FS with Bio-Set (antihemophilic factor [recombinant]) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; May 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KogenateFS.3">
<a name="KogenateFS.3"></a>Kogenate FS with Vial Adapter (antihemophilic factor [recombinant]) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; May 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kovaltry.1">
<a name="Kovaltry.1"></a>Kovaltry (antihemophilic factor [recombinant]) [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9351529">
<a name="9351529"></a>Liesner RJ, “Prophylaxis in Haemophilic Children,” <i>Blood Coagul Fibrinolysis</i>, 1997, 8(Suppl 1):S7-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/9351529/pubmed" id="9351529" target="_blank">9351529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7860443">
<a name="7860443"></a>Lusher JM, “Transfusion Therapy in Congenital Coagulopathies,” <i>Hematol Oncol Clin North Am</i>, 1994, 8(6):1167-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/7860443/pubmed" id="7860443" target="_blank">7860443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7975511">
<a name="7975511"></a>Manucci PM, “Impact of Recombinant Factor VIII on Hemophilia Care,” <i>Vox Sang</i>, 1994, 67(Suppl 3):49-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/7975511/pubmed" id="7975511" target="_blank">7975511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1482660">
<a name="1482660"></a>Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. <i>Br J Haematol</i>. 1992;82(4):729-734.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/1482660/pubmed" id="1482660" target="_blank">1482660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHF.2007">
<a name="NHF.2007"></a>National Hemophilia Foundation (NHF). MASAC recommendations concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). 2007. Available at http://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/masac179.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NHF.1">
<a name="NHF.1"></a>National Hemophilia Foundation (NHF). Medical and Scientific Advisory Council (MASAC) guidelines for perinatal management of women with bleeding disorders and carriers of hemophilia A and B (MASAC document 251). https://www.hemophilia.org/node/3660. Published September 17, 2017. Accessed June 7, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1640190">
<a name="1640190"></a>Nilsson IM, Berntorp E, Lofqvist T, et al, “Twenty-five Years' Experience of Prophylactic Treatment in Severe Haemophilia A and B,” <i>J Intern Med</i>, 1992, 232(1):25-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/1640190/pubmed" id="1640190" target="_blank">1640190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novoeight.1">
<a name="Novoeight.1"></a>Novoeight (antihemophilic factor [recombinant]) [prescribing information]. Plainsboro, NJ: Novo Nordisk Inc; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nuwiq.1">
<a name="Nuwiq.1"></a>Nuwiq (antihemophilic factor [recombinant]) [prescribing information]. Paramus, NJ: Octapharma USA Inc; September 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nuwiq.2">
<a name="Nuwiq.2"></a>Nuwiq (antihemophilic factor [recombinant]) [prescribing information]. Hoboken, NJ: Octapharma; July 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28447403">
<a name="28447403"></a>Pavord S, Rayment R, Madan B, et al; for the Royal College of Obstetricians and Gynaecologists. Management of inherited bleeding disorders in pregnancy: Green-top Guideline No. 71 (joint with UKHCDO). <i>BJOG</i>. 2017;124(8):e193–e263. doi: 10.1111/1471-0528.14592.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/28447403/pubmed" id="28447403" target="_blank">28447403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22503305">
<a name="22503305"></a>Poon MC, Card R. Hemophilia management in transfusion medicine. <i>Transfus Apher Sci</i>. 2012;46(3):299-307. doi:10.1016/j.transci.2012.03.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/22503305/pubmed" id="22503305" target="_blank">22503305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26674820">
<a name="26674820"></a>Prelog T, Dolničar MB, Kitanovski L. Low-dose continuous infusion of factor VIII in patients with haemophilia A. <i>Blood Transfus</i>. 2016;14(5):474-480.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/26674820/pubmed" id="26674820" target="_blank">26674820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Recombinate.1">
<a name="Recombinate.1"></a>Recombinate (antihemophilic factor [recombinant]) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rickard.1">
<a name="Rickard.1"></a>Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. <i>Haemophilia</i>. 1995;1(suppl 1):8-13. doi:10.1111/j.1365-2516.1995.tb00104.x</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20234780">
<a name="20234780"></a>Rossbach HC. Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A. <i>Vasc Health Risk Manag.</i> 2010;6:59-68.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/20234780/pubmed" id="20234780" target="_blank">20234780</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10444280">
<a name="10444280"></a>Scharrer I, Bray GL, and Neutzling O, “Incidence of Inhibitors in Haemophilia A Patients - A Review of Recent Studies of Recombinant and Plasma-Derived Factor VIII Concentrates,” <i>Haemophilia</i>, 1999, 5(3):145-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/10444280/pubmed" id="10444280" target="_blank">10444280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2123300">
<a name="2123300"></a>Schwartz RS, Abildgaard CF, Aledort LM, et al, “Human Recombinant DNA-Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A. Recombinant Factor VIII Study Group,” <i>N Engl J Med</i>, 1990, 323(26):1800-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/2123300/pubmed" id="2123300" target="_blank">2123300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10938981">
<a name="10938981"></a>Shord SS and Lindley CM, “Coagulation Products and Their Uses,” <i>Am J Health Syst Pharm</i>, 2000, 57(15):1403-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/10938981/pubmed" id="10938981" target="_blank">10938981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32744769">
<a name="32744769"></a>Srivastava A, Santagostino E, Dougall A, et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. <i>Haemophilia</i>. 2020;26(suppl 6):1-158. doi:10.1111/hae.14046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/32744769/pubmed" id="32744769" target="_blank">32744769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27704637">
<a name="27704637"></a>Suzuki N, Hirakawa A, Kishimoto M, et al. Retrospective analysis of in vivo recovery and clearance during continuous infusion of recombinant factor VIII products: a single-institution study. <i>Haemophilia</i>. 2017;23(2):215-221. doi:10.1111/hae.13082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/27704637/pubmed" id="27704637" target="_blank">27704637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9873771">
<a name="9873771"></a>Varon D, Martinowitz U. Continuous infusion therapy in haemophilia. <i>Haemophilia</i>. 1998;4(4):431-435.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/9873771/pubmed" id="9873771" target="_blank">9873771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11307831">
<a name="11307831"></a>White GC, Rosendaal F, Aledort LM, et al, “Definitions in Hemophilia. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis,” <i>Thromb Haemost</i>, 2001, 85(3):560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-viii-recombinant-human-pediatric-drug-information/abstract-text/11307831/pubmed" id="11307831" target="_blank">11307831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xyntha.1">
<a name="Xyntha.1"></a>Xyntha (antihemophilic factor [recombinant]) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Xyntha.2">
<a name="Xyntha.2"></a>Xyntha Solofuse (antihemophilic factor [recombinant]) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zonovate.1">
<a name="Zonovate.1"></a>Zonovate (antihemophilic factor [recombinant]) [product monograph]. Mississauga, Ontario, Canada: Novo Nordisk Canada Inc; April 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12757 Version 321.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
